October - 2008

NEWS

Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Ymmunobio Appoints New Chief Operating Officer

Ymmunobio Accepted into Innosuisse Core Coaching

Dr. Katrin Rupalla Interviewed by Global Business Reports

Drug Discovery & Development

Fierce Biotech: Appointment of Michel Janicot

CEACAM1 inhibits Toll-like receptor 2–triggered antibact. responses of pulmonary epithelial cells

Authors: Hortense Slevogt, Solveig Zabel, Bastian Opitz, Andreas Hocke, Julia Eitel, Philippe D N'Guessan, Lothar Lucka, Kristian...